Welcome to our dedicated page for Cytek Biosciences SEC filings (Ticker: CTKB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cytek Biosciences, Inc. filings document the reporting, governance, and security structure of a Nasdaq-listed cell analysis solutions company. Its registered security is common stock traded under the CTKB symbol on the Nasdaq Global Select Market.
The company’s 8-K filings furnish financial-results releases, preliminary revenue updates, and related exhibit disclosures under Item 2.02. Proxy and annual meeting filings cover director elections, advisory executive compensation votes, auditor ratification, stockholder voting results, board-class matters, and other governance subjects. Together, these filings describe Cytek’s public-company reporting framework alongside its business in FSP instruments, reagents, software, services, and cell analysis technologies.
Cytek Biosciences, Inc. reported that Philippe Busque, Ph.D. has submitted his resignation as Senior Vice President, Global Sales and Services. His resignation is effective June 5, 2026 and is described as being to pursue another career opportunity, with no disagreements regarding the company’s operations, policies or practices.
Cytek Biosciences director Michael Holder reported a routine equity compensation event. He acquired 1,454 shares of common stock on May 18, 2026 through the exercise or conversion of restricted stock units, with no open-market purchase or sale involved.
After this transaction, he directly holds 16,721 shares of common stock and 9,457 restricted stock units. The RSU award vests in multiple tranches between August 18, 2024 and August 18, 2025, gradually converting into common shares over time.
Cytek Biosciences, Inc. director Richard Chin reported a routine equity compensation event. On May 18, 2026, he exercised 6,107 Restricted Stock Units, receiving the same number of shares of common stock at a stated price of $0.00 per share.
Following the transaction, Chin directly holds 22,392 shares of Cytek common stock and 50,897 Restricted Stock Units. The RSU Award represents the right to receive one share of common stock per unit and is scheduled to vest in multiple tranches between August 18, 2025 and August 18, 2026.
Cytek Biosciences, Inc. director and Chief Technology Officer Yan Ming reported routine equity compensation activity. On May 18, 2026, Ming exercised restricted stock units that converted into 22,179 shares of common stock in total. To cover tax obligations tied to these vestings, 5,532 shares of common stock were withheld and surrendered to the company at $3.55 per share, rather than sold on the open market. After these transactions, Ming directly owned 4,919,617 shares of Cytek common stock.
Cytek Biosciences SVP Philippe Busque reported compensation-related stock activity. On May 18, 2026, he exercised awards covering 10,464 shares of common stock, converting vested restricted stock units into shares. To cover tax withholding obligations, 2,685 shares were surrendered back to the company at $3.55 per share rather than sold on the open market.
Following these transactions, Busque directly holds 36,448 shares of Cytek Biosciences common stock and 5,641 unvested restricted stock units that may convert into shares as they vest over time under multi-year vesting schedules.
Cytek Biosciences, Inc. President and CEO Wenbin Jiang reported routine equity compensation activity involving restricted stock units that vested into common stock. On May 18, 2026, he exercised RSU awards to acquire 80,062 shares of common stock and had 25,542 shares withheld to cover tax obligations at $3.55 per share.
Following these transactions, Jiang directly held about 5.43 million shares of Cytek common stock and continued to hold 39,275 restricted stock units that will vest over time under multi-year schedules described in the RSU footnotes. No open-market purchases or sales were reported.
Cytek Biosciences Chief Financial Officer William D. McCombe reported routine equity compensation activity tied to Restricted Stock Units on May 18, 2026. He exercised RSU awards into 25,719 shares of common stock and had 9,229 shares withheld at $3.55 per share to cover tax obligations. Following these transactions, he directly holds 98,739 shares of common stock. The footnotes explain that each RSU represents a contingent right to one share and outline multi-year vesting schedules, indicating these events stem from scheduled vesting rather than open-market trades.
Cytek Biosciences, Inc.’s chief legal officer Valerie Barnett reported routine equity compensation activity. On May 18, 2026, she exercised 24,295 Restricted Stock Units into common shares and had 8,719 shares withheld at $3.55 per share to cover tax obligations.
These tax-withholding dispositions were not open-market sales. After the transactions, she directly held 136,009 shares of common stock and continued to hold 12,280 Restricted Stock Units, reflecting ongoing equity-based compensation rather than discretionary trading.
Cytek Biosciences, Inc. reports an amended Schedule 13G/A identifying large passive holders and a joint filing agreement. The amendment lists Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander as filing participants. The cover entries show shared voting and dispositive power positions of 6,974,492 shares (5.4%) and 7,872,900 shares (6.1%) for listed filers. The filing states these securities are held by entities subject to voting control and investment discretion by Millennium-related managers and attaches a Joint Filing Agreement dated May 15, 2026.
Cytek Biosciences, Inc. reported revenue of $44.1 million for the three months ended March 31, 2026, up from $41.5 million a year earlier, driven by both product and service sales. Direct sales contributed 69% of revenue, with distributors providing the remainder.
The company recorded a net loss of $18.9 million, compared with $11.4 million in the prior-year quarter, as operating expenses, particularly general and administrative costs, increased. Gross profit was $21.3 million. Cash and cash equivalents were $65.7 million and marketable securities were $196.6 million, supporting total assets of $449.1 million against total liabilities of $121.5 million.